Chemo + immunotherapy may improve bladder preservation, interim data from phase II study show

Cell Painting identifies flavonoids that are toxic to bladder cancer cells

A team led by researchers at Baylor College of Medicine has identified flavonoids, natural compounds found in plants, that are toxic to bladder cancer cells cultured in the lab.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Wistar scientists uncover new viral mechanism for evading immunity, identifying a new drug target

Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram mitochondrial structure to silence immune responses and ensure successful viral reproduction.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

Mayo Clinic researchers have established the world’s first biobank of human salivary gland tissue-organoids to study chronic dry mouth, or xerostomia, an agonizing side effect of damaged salivary glands that affects millions.

May 23, 2025

Vol.51 No.20

In Brief

OncoHost awarded €2.5M grant from the EIC Transition Programme to advance precision oncology

OncoHost, together with its partners Heidelberg University Hospital, European Institute of Oncology and Virgen Macarena University Hospital, announced on May 15 that the parties have been awarded a €2.5 million grant from the EIC Transition Program of Horizon Europe.

May 16, 2025

Vol.51 No.19

Drugs & Targets

RyboDyn expands strategic cancer immunotherapy collaboration with Moffitt Cancer Center

RyboDyn, Inc. announced on May 15 the expansion of its strategic collaboration with Moffitt Cancer Center, a global leader in cancer care and research.

May 16, 2025

Vol.51 No.19

Clinical

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.

May 02, 2025

Vol.51 No.17

By Jacquelyn Cobb

Chemo + immunotherapy may improve bladder preservation, interim data from phase II study show

YOU MAY BE INTERESTED IN

Cell Painting identifies flavonoids that are toxic to bladder cancer cells

Wistar scientists uncover new viral mechanism for evading immunity, identifying a new drug target

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

OncoHost awarded €2.5M grant from the EIC Transition Programme to advance precision oncology

RyboDyn expands strategic cancer immunotherapy collaboration with Moffitt Cancer Center

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Renew today!

Subscriber content

Never miss an issue!

Login